Published in Am J Pathol on March 01, 1996
Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest (2001) 1.42
Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol (2010) 1.25
Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol (2009) 1.21
Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol (2004) 0.91
Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol (2009) 0.91
Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol (2011) 0.83
Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. Arch Dermatol Res (2007) 0.81
Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist. Virchows Arch (2003) 0.80
Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid. Clin Exp Immunol (2006) 0.78
Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol (2011) 0.77
Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid. PLoS One (2014) 0.76
Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS One (2015) 0.76
Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid. Exp Dermatol (2015) 0.75
Mast cell regulation of the immune response. World Allergy Organ J (2009) 0.75
Eosinophils in Autoimmune Diseases. Front Immunol (2017) 0.75
Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med (1988) 3.50
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol (1990) 2.00
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med (1991) 1.77
Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid. J Clin Invest (1973) 1.73
The biology of the eosinophilic leukocyte. Annu Rev Med (1993) 1.65
Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol (1983) 1.36
Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 1.35
92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest (1994) 1.26
An immunofluorescent method for specific staining of eosinophil granule major basic protein. J Immunol Methods (1981) 1.26
Eosinophil granule proteins in peripheral blood granulocytes. J Leukoc Biol (1992) 1.24
The complement system in bullous pemphigoid. III. Fixation of C1q and C4 by pemphigoid antibody. J Lab Clin Med (1975) 1.24
An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol (1982) 1.23
Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med (1978) 1.16
Cytokine generation by eosinophils. J Allergy Clin Immunol (1994) 1.16
Conjugated avidin identifies cutaneous rodent and human mast cells. J Invest Dermatol (1984) 1.12
Bullous pemphigoid. J Am Acad Dermatol (1987) 1.10
Hemopoietins for eosinophils. Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease. Hematol Oncol Clin North Am (1989) 1.08
Mechanism of lesion production in pemphigus and pemphigoid. J Am Acad Dermatol (1982) 1.04
Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol (1990) 1.02
Cellular events leading to blister formation in bullous pemphigoid. Br J Dermatol (1980) 0.96
The pathogenic mechanisms of blister formation in bullous pemphigoid. J Invest Dermatol (1982) 0.95
Bullous pemphigoid, herpes gestationis and linear dermatitis herpetiformis: circulating anti-basement membrane zone antibodies; in vitro studies. J Invest Dermatol (1980) 0.95
Comparison of antifading agents used in immunofluorescence. J Immunol Methods (1989) 0.93
Bullous pemphigoid blister fluid stimulates eosinophil colony formation and activates eosinophils. Clin Exp Immunol (1982) 0.91
Deposition of the membrane attack complex of complement in bullous pemphigoid. J Invest Dermatol (1984) 0.90
Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein. J Exp Med (1983) 0.90
Abolition of non-specific fluorescent staining of eosinophils. J Immunol Methods (1974) 0.89
Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol (1993) 0.89
Ultrastructural localization of in vivo-bound complement in bullous pemphigoid. J Invest Dermatol (1975) 0.87
Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction. Lab Invest (1990) 0.86
Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol (1993) 0.82
Leukocyte chemotaxis to the dermal-epidermal junction of human skin mediated by pemphigoid antibody and complement: mechanism of cell attachment in the in vitro leukocyte attachment method. J Invest Dermatol (1981) 0.82
Demonstration of the complement regulating protein, beta 1H, in skin biopsies from patients with bullous pemphigoid. J Invest Dermatol (1979) 0.81
The molecular pathogenesis of bullous pemphigoid. Clin Dermatol (1987) 0.80
Cytokine profile of patients with bullous pemphigoid. Br J Dermatol (1994) 0.79
Ultrastructural aspects of infiltrated eosinophils in bullous pemphigoid. J Dermatol (1992) 0.77
Analysis of pregnancy-associated major basic protein levels throughout gestation. Placenta (1994) 0.77
Eosinophil phenotypes in bullous pemphigoid. J Dermatol (1992) 0.77
Alteration in the density, morphology, and biological properties of eosinophils produced by bullous pemphigoid blister fluid. Arch Dermatol Res (1989) 0.77
Mast cell and eosinophil mediated damage in bullous pemphigoid. Immunol Ser (1989) 0.76
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Circulating adhesion molecules in disease. Immunol Today (1993) 6.22
Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med (1996) 5.69
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med (1997) 5.18
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52
The eosinophilic leukocyte: structure and function. Adv Immunol (1986) 4.08
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res (1988) 3.47
Measurement of IgE in normal and allergic serum by radioimmunoassay. J Lab Clin Med (1971) 3.47
Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis (1988) 3.45
Activation-independent binding of human memory T cells to adhesion molecule ELAM-1. Nature (1991) 3.45
Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev (1992) 3.42
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33
Lymphocyte interactions with endothelial cells. Immunol Today (1992) 3.31
Histochemical Studies on Tissue Enzymes: III. A Study of the Distribution of Acid Phosphatases with Special Reference to the Nervous System. Am J Pathol (1943) 3.31
Cytotoxic properties of the eosinophil major basic protein. J Immunol (1979) 3.29
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med (1990) 3.05
The nerve fiber layer in the diagnosis of glaucoma. Arch Ophthalmol (1977) 2.94
IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol (1992) 2.89
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis (1993) 2.83
Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 2.81
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Appropriateness of coronary angiography after myocardial infarction among Medicare beneficiaries. Managed care versus fee for service. N Engl J Med (2000) 2.75
Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest (1980) 2.70
3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayo Clin Proc (1992) 2.64
A comparison of reinforcer assessment methods: the utility of verbal and pictorial choice procedures. J Appl Behav Anal (1996) 2.63
Clinical evaluation of nerve fiber layer atrophy as an indicator of glaucomatous optic nerve damage. Arch Ophthalmol (1980) 2.49
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med (1992) 2.38
Couples' patterns of adjustment to colon cancer. Soc Sci Med (2000) 2.33
The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol (1986) 2.29
Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol (1991) 2.27
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 2.22
Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet (1982) 2.21
The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies. J Clin Invest (1976) 2.19
Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13
Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol (1994) 2.11
Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis (1989) 2.08
The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med (1990) 2.06
Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis. N Engl J Med (1990) 2.05
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol (1997) 2.04
T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol (1990) 2.00
Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet (1987) 1.98
Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest (1976) 1.96
The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A (1999) 1.90
Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med (1998) 1.90
The flashlight test and van Herick's test are poor predictors for occludable angles. Aust N Z J Ophthalmol (1996) 1.88
Identification of a major basic protein in guinea pig eosinophil granules. J Exp Med (1973) 1.87
Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci U S A (1981) 1.85
Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc (1981) 1.85
Purification of myeloperoxidases from the bone marrow of the guinea pig. Biochemistry (1969) 1.84
The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity (1996) 1.84
Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med (1989) 1.83
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med (1990) 1.80
Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med (1985) 1.79
Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment. Mayo Clin Proc (1997) 1.78
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med (1991) 1.77
Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol (1994) 1.75
Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology (1996) 1.74
Production of human immunoglobulin E antibody in vitro. J Immunol (1979) 1.73
Interleukin 2 induces gamma-interferon production: participation of macrophages and NK-like cells. J Immunol (1983) 1.72
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71
Eosinophils 1992. Immunol Today (1992) 1.69
Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med (1983) 1.69
Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A (1986) 1.67
Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol (1986) 1.65
The biology of the eosinophilic leukocyte. Annu Rev Med (1993) 1.65
Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol (1989) 1.64
Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis (1987) 1.62
Physiochemical and biological properties of the major basic protein from guinea pig eosinophil granules. J Exp Med (1974) 1.61
Selective stimulation and purification of eosinophils and neutrophils from guinea pig peritoneal fluids. J Lab Clin Med (1973) 1.61
Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol (1991) 1.60
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest (1991) 1.60
Bone-marrow transplantation for leukaemia. Lancet (1995) 1.60
Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (1998) 1.59
Review of biomarkers in colorectal cancer. Colorectal Dis (2012) 1.59
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med (1994) 1.58
Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol (1992) 1.58
Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. J Am Acad Dermatol (1998) 1.55
Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology (1999) 1.54
The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? J Allergy Clin Immunol (1982) 1.53
Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest (1993) 1.53
Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis (1988) 1.52
Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosinophilic disorder. Clin Exp Allergy (1993) 1.52
Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol (1997) 1.52
Antibody formation in dysgammaglobulinemia. J Clin Invest (1966) 1.50